Fluidic Sciences acquires business and assets of Sphere Bio
Combined portfolio unites Fluidic Sciences’ in‑solution microfluidic diffusional sizing technology with Sphere Bio’s proprietary picodroplet-microfluidic platforms, Cyto‑Mine Chroma, and high‑throughput assays – delivering end‑to‑end insight from cells to molecules
9 Oct 2025
Fluidic Sciences has purchased the business and assets of Sphere Bio Ltd. The transaction creates a powerful, complementary technology suite that enables researchers to seamlessly traverse cellular function and molecular binding, accelerating biotherapeutic discovery and development.
Sphere Bio’s proprietary picodroplet systems and Cyto‑Mine® Chroma multiplexing platform deliver rapid, high‑fidelity, single‑cell screening, isolation, and monoclonality assurance. These capabilities align with Fluidic Sciences’ Microfluidic Diffusional Sizing (MDS) platform — an immobilization‑free, in‑solution approach that measures binding affinity (Kd), stoichiometry, and concentration directly in complex matrices — to offer a uniquely integrated workflow from cell to molecular mechanism.
Fluidic Sciences will integrate Sphere Bio’s teams over the coming months, aligning roadmap priorities and maintaining uninterrupted customer support. In the immediate term, both brands will continue in market; a unified solutions roadmap and cross‑workflow application notes will follow.
Dr. James Wilkinson, CEO, Fluidic Sciences, commented, “By bringing Sphere Bio into Fluidic Sciences, we’re pairing high‑throughput functional cell screening with definitive in‑solution interaction measurements — creating an end‑to‑end workflow that accelerates discovery and de‑risks development”
“We are excited to combine our single-cell expertise with Fluidic Sciences’ in-solution technologies to deliver integrated solutions that accelerate discovery. Within Fluidic Sciences, we’ll continue innovating and expanding applications for picodroplets and Cyto‑Mine Chroma — now connected to powerful in‑solution biophysics,” said Richard Hammond, CTO, Sphere Bio.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Links
Tags
Frequently asked questions
Show frequently asked questions
What does Fluidic Sciences’ acquisition of Sphere Bio mean for biotherapeutic discovery?
The acquisition combines Sphere Bio’s high-throughput single-cell screening and picodroplet technologies with Fluidic Sciences’ in-solution molecular interaction measurements. The integrated workflow will help researchers move from cellular function to molecular binding, accelerating biotherapeutic discovery and reducing development risk.
How will Cyto-Mine® Chroma complement Fluidic Sciences’ Microfluidic Diffusional Sizing platform?
Cyto-Mine Chroma provides rapid, high-fidelity single-cell screening, isolation, multiplexing, and monoclonality assurance. Fluidic Sciences’ immobilization-free Microfluidic Diffusional Sizing platform measures binding affinity (Kd), stoichiometry, and concentration directly in complex matrices. Together, they create an integrated workflow from cells to molecular mechanisms.
What will happen to Sphere Bio’s teams, brands, and customer support after the acquisition?
Fluidic Sciences will integrate Sphere Bio’s teams over the coming months and align technology roadmap priorities. Both Fluidic Sciences and Sphere Bio will remain in the market in the immediate term, with uninterrupted customer support. A unified solutions roadmap and cross-workflow application notes will follow.